$AVGR
Avinger Inc Stock $avgr

$avgr Overview Financials Valuation SEC Filings Company Website

2021 Q3 Form 10-Q Financial Statement

#000143774921019333 Filed on August 10, 2021

Income Statement

Concept	2021 Q3	2021 Q2	2020 Q2
Revenue	$2.366M	$2.802M	$1.466M
YoY Change	2.78%	91.13%	-36.78%
Cost Of Revenue	$1.566M	$1.784M	$1.107M
YoY Change	2.69%	61.16%	-30.77%
Gross Profit	$800.0K	$1.018M	$359.0K
YoY Change	2.96%	183.57%	-50.14%
Gross Profit Margin	33.81%	36.33%	24.49%
Selling, General & Admin	$3.892M	$3.918M	$2.654M
YoY Change	12.45%	47.63%	-35.13%
% of Gross Profit	486.5%	384.87%	739.28%
Research & Development	$1.397M	$1.507M	$1.297M
YoY Change	-1.41%	16.19%	-2.85%
% of Gross Profit	174.63%	148.04%	361.28%
Depreciation & Amortization	$158.0K	$177.0K	$220.0K
YoY Change	-31.3%	-19.55%	-4.35%
% of Gross Profit	19.75%	17.39%	61.28%
Operating Expenses	$5.289M	$5.425M	$3.951M
YoY Change	8.43%	37.31%	-27.18%
Operating Profit	-$4.489M	-$4.407M	-$3.592M
YoY Change	9.46%	22.69%	-23.67%
Interest Expense	$419.0K	$399.0K	$414.0K
YoY Change	-3.23%	-3.62%	13.74%
% of Operating Profit
Other Income/Expense, Net	-$4.000K	$2.354M	$4.000K
YoY Change	-150.0%	58750.0%	-98.78%
Pretax Income	-$4.912M	-$2.452M	-$4.000M
YoY Change	8.43%	-38.7%	-13.98%
Income Tax
% Of Pretax Income
Net Earnings	-$4.912M	-$2.452M	-$4.000M
YoY Change	8.55%	-38.7%	-14.0%
Net Earnings / Revenue	-207.61%	-87.51%	-272.85%
Basic Earnings Per Share	-$1.25	-$0.73
Diluted Earnings Per Share	-$1.030M	-$514.3K	-$146.5K
COMMON SHARES
Basic Shares Outstanding	95.35M	4.768M
Diluted Shares Outstanding

Balance Sheet

Concept	2021 Q3	2021 Q2	2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$23.08M	$26.70M	$16.55M
YoY Change	-8.89%	61.33%	12.2%
Cash & Equivalents	$23.10M	$26.70M	$16.55M
Short-Term Investments
Other Short-Term Assets	$668.0K	$1.112M	$900.0K
YoY Change	28.46%	23.56%	18.42%
Inventory	$4.519M	$4.118M	$4.157M
Prepaid Expenses
Receivables	$1.400M	$1.788M	$1.076M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$29.67M	$33.72M	$22.68M
YoY Change	-4.87%	48.66%	8.88%
LONG-TERM ASSETS
Property, Plant & Equipment	$213.0K	$355.0K	$1.140M
YoY Change	-77.39%	-68.86%	-43.17%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$452.0K	$486.0K	$594.0K
YoY Change	-17.82%	-18.18%	54.69%
Total Long-Term Assets	$4.073M	$4.471M	$6.202M
YoY Change	-29.3%	-27.91%	-22.34%
TOTAL ASSETS
Total Short-Term Assets	$29.67M	$33.72M	$22.68M
Total Long-Term Assets	$4.073M	$4.471M	$6.202M
Total Assets	$33.74M	$38.19M	$28.88M
YoY Change	-8.68%	32.22%	0.23%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.178M	$1.037M	$924.0K
YoY Change	86.39%	12.23%	-14.92%
Accrued Expenses	$791.0K	$764.0K	$730.0K
YoY Change	15.81%	4.66%	-5.93%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$0.00	$10.81M
YoY Change	-100.0%	-100.0%	31.83%
Total Short-Term Liabilities	$7.439M	$6.490M	$16.31M
YoY Change	-58.88%	-60.21%	13.63%
LONG-TERM LIABILITIES
Long-Term Debt	$11.85M	$11.43M	$1.300M
YoY Change	1202.53%	779.54%
Other Long-Term Liabilities	$431.0K	$287.0K	$19.00K
YoY Change	4688.89%	1410.53%	72.73%
Total Long-Term Liabilities	$431.0K	$287.0K	$19.00K
YoY Change	4688.89%	1410.53%	72.73%
TOTAL LIABILITIES
Total Short-Term Liabilities	$7.439M	$6.490M	$16.31M
Total Long-Term Liabilities	$431.0K	$287.0K	$19.00K
Total Liabilities	$22.17M	$20.91M	$21.34M
YoY Change	-1.42%	-2.01%	12.89%
SHAREHOLDERS EQUITY
Retained Earnings	-$379.8M	-$374.8M	-$358.2M
YoY Change	4.71%	4.64%	5.79%
Common Stock	$391.3M	$392.1M	$365.7M
YoY Change	3.75%	7.22%	4.94%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$11.57M	$17.28M	$7.549M
YoY Change
Total Liabilities & Shareholders Equity	$33.74M	$38.19M	$28.88M
YoY Change	-8.68%	32.22%	0.23%

Cashflow Statement

Concept	2021 Q3	2021 Q2	2020 Q2
OPERATING ACTIVITIES
Net Income	-$4.912M	-$2.452M	-$4.000M
YoY Change	8.55%	-38.7%	-14.0%
Depreciation, Depletion And Amortization	$158.0K	$177.0K	$220.0K
YoY Change	-31.3%	-19.55%	-4.35%
Cash From Operating Activities	-$3.622M	-$3.744M	-$3.430M
YoY Change	10.76%	9.15%	-5.25%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	-$8.000K	$0.00
YoY Change			-100.0%
Acquisitions
YoY Change
Other Investing Activities	$0.00		$0.00
YoY Change	-100.0%
Cash From Investing Activities	$0.00	-$8.000K	$0.00
YoY Change	-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	-3.000K	10.11M
YoY Change	-100.0%	-100.03%	505.39%
NET CHANGE
Cash From Operating Activities	-3.622M	-3.744M	-3.430M
Cash From Investing Activities	0.000	-8.000K	0.000
Cash From Financing Activities	0.000	-3.000K	10.11M
Net Change In Cash	-3.622M	-3.755M	6.680M
YoY Change	-141.25%	-156.21%	-442.56%
FREE CASH FLOW
Cash From Operating Activities	-$3.622M	-$3.744M	-$3.430M
Capital Expenditures	$0.00	-$8.000K	$0.00
Free Cash Flow	-$3.622M	-$3.736M	-$3.430M
YoY Change		8.92%	-4.99%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	95353002
CY2021Q2	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	6000	USD
CY2021Q2	us-gaap	Inventory Net InventoryNet	4118000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	3876000	USD
CY2021Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	95353002
CY2021Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	95353002
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	84926129
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	84926129
	us-gaap	Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation	0
	us-gaap	Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation	0
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	pure
CY2021Q2	us-gaap	Operating Lease Expense OperatingLeaseExpense	314000	USD
	us-gaap	Operating Lease Expense OperatingLeaseExpense	628000	USD
CY2021Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	2753999
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0
CY2021Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1037000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	694000	USD
CY2021Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1667000	USD
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0
	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	0	USD
CY2020Q2	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	0	USD
	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	0	USD
CY2021Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	26700000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	22185000	USD
CY2021Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1788000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1484000	USD
CY2020Q4	us-gaap	Assets Assets	33195000	USD
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	19000	USD
CY2021Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2021Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	52276
CY2021Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	52276
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	52369
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	52369
CY2021Q2	us-gaap	Preferred Stock Liquidation Preference Value PreferredStockLiquidationPreferenceValue	52191000	USD
CY2020Q4	us-gaap	Preferred Stock Liquidation Preference Value PreferredStockLiquidationPreferenceValue	52191000	USD
CY2021Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2021Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1112000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	350000	USD
CY2021Q2	us-gaap	Assets Current AssetsCurrent	33718000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	27895000	USD
CY2021Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3630000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4063000	USD
CY2021Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	355000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	727000	USD
CY2021Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	486000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	510000	USD
CY2021Q2	us-gaap	Assets Assets	38189000	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1703000	USD
CY2021Q2	us-gaap	Dividends Payable Current DividendsPayableCurrent	2088000	USD
CY2020Q4	us-gaap	Dividends Payable Current DividendsPayableCurrent	0	USD
CY2021Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	764000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	669000	USD
CY2021Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	934000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	806000	USD
CY2021Q2	us-gaap	Secured Debt Current SecuredDebtCurrent	0	USD
CY2020Q4	us-gaap	Secured Debt Current SecuredDebtCurrent	3590000	USD
CY2021Q2	us-gaap	Liabilities Current LiabilitiesCurrent	6490000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	7462000	USD
CY2021Q2	us-gaap	Secured Long Term Debt SecuredLongTermDebt	11434000	USD
CY2020Q4	us-gaap	Secured Long Term Debt SecuredLongTermDebt	9400000	USD
CY2021Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2696000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3257000	USD
CY2021Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	287000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	0	USD
CY2021Q2	us-gaap	Liabilities Liabilities	20907000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	20119000	USD
CY2021Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2021Q2	us-gaap	Common Stock Value CommonStockValue	95000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	85000	USD
CY2021Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	392032000	USD
CY2020Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	380332000	USD
CY2021Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-374845000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-367341000	USD
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	17282000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	13076000	USD
CY2021Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	38189000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	33195000	USD
CY2021Q2	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	2802000	USD
CY2020Q2	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	1466000	USD
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	5361000	USD
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	3727000	USD
CY2021Q2	us-gaap	Cost Of Revenue CostOfRevenue	1784000	USD
CY2020Q2	us-gaap	Cost Of Revenue CostOfRevenue	1107000	USD
	us-gaap	Cost Of Revenue CostOfRevenue	3449000	USD
	us-gaap	Cost Of Revenue CostOfRevenue	2867000	USD
CY2021Q2	us-gaap	Gross Profit GrossProfit	1018000	USD
CY2020Q2	us-gaap	Gross Profit GrossProfit	359000	USD
	us-gaap	Gross Profit GrossProfit	1912000	USD
	us-gaap	Gross Profit GrossProfit	860000	USD
CY2021Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1507000	USD
CY2020Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1297000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3105000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2891000	USD
CY2021Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3918000	USD
CY2020Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2654000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	7863000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	7040000	USD
CY2021Q2	us-gaap	Operating Expenses OperatingExpenses	5425000	USD
CY2020Q2	us-gaap	Operating Expenses OperatingExpenses	3951000	USD
	us-gaap	Operating Expenses OperatingExpenses	10968000	USD
	us-gaap	Operating Expenses OperatingExpenses	9931000	USD
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-4407000	USD
CY2020Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-3592000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-9056000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-9071000	USD
CY2021Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	1000	USD
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	27000	USD
CY2020Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	2000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	3000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	32000	USD
CY2021Q2	us-gaap	Interest Expense InterestExpense	400000	USD
CY2020Q2	us-gaap	Interest Expense InterestExpense	414000	USD
	us-gaap	Interest Expense InterestExpense	798000	USD
	us-gaap	Interest Expense InterestExpense	812000	USD
CY2021Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2354000	USD
CY2020Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	4000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2347000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	0	USD
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-2452000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-4000000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-7504000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-9851000	USD
CY2021Q2	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	1044000	USD
CY2020Q2	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	967000	USD
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	2088000	USD
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	1934000	USD
CY2021Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3496000	USD
CY2020Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4967000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-9592000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-11785000	USD
CY2021Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.04
CY2020Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.18
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.10
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.56
CY2021Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	95352000
CY2020Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	27310000
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	93404000
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	20963000
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	4408000	USD
CY2020Q2	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	9000	USD
CY2020Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	325000	USD
CY2020Q2	us-gaap	Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings	967000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-4000000	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	7549000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	20475000	USD
CY2021Q2	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	0	USD
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	303000	USD
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings	1044000	USD
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-2452000	USD
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	17282000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	6895000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	776000	USD
	us-gaap	Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings	1934000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-9851000	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	7549000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	13076000	USD
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	0	USD
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	0	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	721000	USD
	us-gaap	Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings	2088000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-7504000	USD
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	17282000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-7504000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-9851000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	367000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	453000	USD
	avgr	Noncash Interest Expense Income And Other Charges Net NoncashInterestExpenseIncomeAndOtherChargesNet	753000	USD
	avgr	Noncash Interest Expense Income And Other Charges Net NoncashInterestExpenseIncomeAndOtherChargesNet	728000	USD
	avgr	Change In Rightofuse Asset ChangeInRightofuseAsset	68000	USD
	avgr	Change In Rightofuse Asset ChangeInRightofuseAsset	86000	USD
	avgr	Proceeds From The Issuance Of Common Stock Under Officers And Directors Purchase Plan ProceedsFromTheIssuanceOfCommonStockUnderOfficersAndDirectorsPurchasePlan	0	USD
	avgr	Proceeds From The Issuance Of Common Stock Under Officers And Directors Purchase Plan ProceedsFromTheIssuanceOfCommonStockUnderOfficersAndDirectorsPurchasePlan	36000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	13077000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	14002000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	44000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	84000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	721000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	776000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	4515000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	5607000	USD
	us-gaap	Inventory Write Down InventoryWriteDown	22000	USD
	us-gaap	Inventory Write Down InventoryWriteDown	253000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-10000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	29000	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	2353000	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-0	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	314000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-382000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	241000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	465000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	762000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	532000	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	44000	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-4000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	343000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	261000	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-36000	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-631000	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	95000	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	76000	USD
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	287000	USD
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	10000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8544000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8395000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	18000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	-0	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-18000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	USD
	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	0	USD
	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	2330000	USD
	avgr	Proceeds From The Issuance Of Common Stock And Convertible Preferred Stock Net Of Issuance Costs ProceedsFromTheIssuanceOfCommonStockAndConvertiblePreferredStockNetOfIssuanceCosts	13077000	USD
	avgr	Proceeds From The Issuance Of Common Stock And Convertible Preferred Stock Net Of Issuance Costs ProceedsFromTheIssuanceOfCommonStockAndConvertiblePreferredStockNetOfIssuanceCosts	11636000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	22185000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	10943000	USD
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	26700000	USD
CY2020Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	16550000	USD
	avgr	Accretion Of Preferred Stock Dividends AccretionOfPreferredStockDividends	2088000	USD
	avgr	Accretion Of Preferred Stock Dividends AccretionOfPreferredStockDividends	1934000	USD
	avgr	Reclassification Of Right Of Use Asset To Prepaid Rent ReclassificationOfRightOfUseAssetToPrepaidRent	-68000	USD
	avgr	Reclassification Of Right Of Use Asset To Prepaid Rent ReclassificationOfRightOfUseAssetToPrepaidRent	-86000	USD
	avgr	Transfer Between Inventories And Property And Equipment TransferBetweenInventoriesAndPropertyAndEquipment	-23000	USD
	avgr	Transfer Between Inventories And Property And Equipment TransferBetweenInventoriesAndPropertyAndEquipment	-32000	USD
	us-gaap	Nature Of Operations NatureOfOperations	<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b/></p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><em style="font: inherit;">1.</em> Organization</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Organization, Nature of Business</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Avinger, Inc. (the “Company”), a Delaware corporation, was incorporated in <em style="font: inherit;"> March </em><em style="font: inherit;">2007.</em> The Company designs, manufactures and sells image-guided, catheter-based systems that are used by physicians to treat patients with peripheral artery disease (“PAD”). Patients with PAD have a build-up of plaque in the arteries that supply blood to areas away from the heart, particularly the pelvis and legs. The Company manufactures and sells a suite of products in the United States (“U.S.”) and in select international markets. The Company has developed its Lumivascular platform, which integrates optical coherence tomography (<em style="font: inherit;"> “OCT”) </em>visualization with interventional catheters and is the industry’s only system that provides real-time intravascular imaging during the treatment portion of PAD procedures. The Company’s Lumivascular platform consists of a capital component, our Lightbox console, as well as a variety of disposable catheter products. The Company’s current catheter products include its non-imaging catheters, Wildcat and <em style="font: inherit;">Kittycat2,</em> as well as its Lumivascular platform products, Ocelot, Ocelot PIXL, Ocelot MVRX and Tigereye, all of which are designed to allow physicians to penetrate a total blockage in an artery, known as a chronic total occlusion (“CTO”). The Company also has image-guided atherectomy solutions under its suite of Lumivascular products, Pantheris and Pantheris SV, which are designed to allow physicians to precisely remove arterial plaque in PAD patients. The Company is located in Redwood City, California.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Liquidity Matters</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">In the course of its activities, the Company has incurred losses and negative cash flows from operations since its inception. As of <em style="font: inherit;"> June 30, 2021, </em>the Company had an accumulated deficit of $374.8 million. The Company expects to incur losses for the foreseeable future. The Company believes that its cash and cash equivalents of $26.7 million at <em style="font: inherit;"> June 30, 2021 </em>and expected revenues and funds from operations will be sufficient to allow the Company to fund its current operations through <em style="font: inherit;">2022.</em> The Company received net proceeds of approximately $3.9 million from the sale of its common stock in its <em style="font: inherit;"> January 2020 </em>offering, $2.3 million of loan proceeds in <em style="font: inherit;"> April 2020 </em>pursuant to the Paycheck Protection Program (“PPP”) under the Coronavirus Aid, Relief and Economic Security (“CARES”) Act, $3.0 million from the sale of its common stock in <em style="font: inherit;"> April </em>and <em style="font: inherit;"> May 2020, </em>$5.5 million from the sale of its common stock in <em style="font: inherit;"> June </em>and <em style="font: inherit;"> July 2020, </em>$11.3 million from the sale of its common stock in <em style="font: inherit;"> August </em>and <em style="font: inherit;"> September 2020, </em>and approximately $13.1 million from the sale of its common stock in <em style="font: inherit;"> February 2021. </em>The Company does <em style="font: inherit;">not</em> have any immediate plans to raise additional funds through future equity or debt financings. However, the Company <em style="font: inherit;"> may </em>decide to raise additional funds to meet its operational needs and capital requirements for product development, clinical trials and commercialization or other strategic objectives.</p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The Company can provide <em style="font: inherit;">no</em> assurance that it will be successful in raising funds pursuant to additional equity or debt financings or that such funds will be raised at prices that do <em style="font: inherit;">not</em> create substantial dilution for its existing stockholders. Given the volatility in the Company’s stock price, any financing that it <em style="font: inherit;"> may </em>undertake in the next <em style="font: inherit;">twelve</em> months could cause substantial dilution to its existing stockholders, there can be <em style="font: inherit;">no</em> assurance that the Company will be successful in acquiring additional funding at levels sufficient to fund its various endeavors. In addition, the COVID-<em style="font: inherit;">19</em> pandemic and responses thereto have resulted in reduced consumer and investor confidence, instability in the credit and financial markets, volatile corporate profits, restrictions on elective medical procedures, and reduced business and consumer spending, which could increase the cost of capital and/or limit the availability of capital to the Company. During the <em style="font: inherit;">second</em> quarter of <em style="font: inherit;">2020</em> the Company took certain actions to manage available cash and other resources to mitigate the effects of COVID-<em style="font: inherit;">19</em> on its business, which included reduction of discretionary costs, reduction of base salaries for all of its non-manufacturing employees by 20% and reduction of hours worked by its manufacturing workers by 20%. Salaries and hours worked largely returned to prior levels by <em style="font: inherit;"> July 2020.</em></p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">If the Company is unable to raise additional capital in sufficient amounts or on terms acceptable to it, the Company <em style="font: inherit;"> may </em>have to significantly reduce its operations or delay, scale back or discontinue the development of <em style="font: inherit;">one</em> or more of its products. The financial statements do <em style="font: inherit;">not</em> include any adjustments that might result from the outcome of this uncertainty. The Company’s ultimate success will largely depend on its continued development of innovative medical technologies, its ability to successfully commercialize its products and its ability to raise significant additional funding. </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Public Offerings</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">On <em style="font: inherit;"> January 31, 2020, </em>the Company completed a public offering of 6,428,572 shares of common stock at an offering price of $0.70 per share. As a result, the Company received net proceeds of approximately $3.9 million after underwriting discounts, commissions, legal and accounting fees, and other ancillary expenses. Due to anti-dilution provisions, the conversion price of the outstanding shares of Series B preferred stock, which was issued in our <em style="font: inherit;"> February 2018 </em>offering, was reduced to <em style="font: inherit;">$0.70</em> per share.</p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">On <em style="font: inherit;"> April 30, 2020, </em>the Company completed a public offering of 12,600,000 shares of common stock at an offering price of $0.25 per share. On <em style="font: inherit;"> May 6, 2020 </em>the Company issued an additional 1,890,000 shares of common stock at the same offering price pursuant to the exercise in full of the underwriter’s over-allotment option in connection with the aforementioned offering. As a result, the Company received aggregate net proceeds of approximately $3.0 million after underwriting discounts, commissions, legal and accounting fees, and other ancillary expenses. Due to anti-dilution provisions, the conversion price of the outstanding shares of Series B preferred stock, which was issued in our <em style="font: inherit;"> February 2018 </em>offering, was reduced to <em style="font: inherit;">$0.25</em> per share.</p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">On <em style="font: inherit;"> June 26, 2020, </em>the Company completed a public offering of 20,000,000 shares of common stock at an offering price of $0.27 per share. On <em style="font: inherit;"> July 9, 2020 </em>the Company issued an additional 3,000,000 shares of common stock at the same offering price pursuant to the exercise in full of the underwriter’s over-allotment option in connection with the aforementioned offering resulting in $0.7 million of additional net proceeds. As a result, the Company received aggregate net proceeds of approximately $5.5 million including the overallotment option and after underwriting discounts, commissions, legal and accounting fees, and other ancillary expenses.</p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">On <em style="font: inherit;"> August 6, 2020, </em>under the Shelf Registration Statement, the Company completed a public offering of 15,789,474 shares of common stock at an offering price of $0.38 per share. On <em style="font: inherit;"> August 11, 2020 </em>the Company issued an additional 2,368,421 shares of common stock at the same offering price pursuant to the exercise in full of the underwriter’s over-allotment option in connection with the aforementioned offering. As a result, the Company received aggregate net proceeds of approximately $6.2 million after underwriting discounts, commissions, legal and accounting fees, and other ancillary expenses.</p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">On <em style="font: inherit;"> August 25, 2020, </em>under the Shelf Registration Statement, the Company completed a public offering of 11,063,830 shares of common stock at an offering price of $0.47 per share. On <em style="font: inherit;"> September 1, 2020 </em>the Company issued an additional 1,000,000 shares of common stock at the same offering price pursuant to the exercise in full of the underwriter’s over-allotment option in connection with the aforementioned offering. As a result, the Company received aggregate net proceeds of approximately $5.1 million after underwriting discounts, commissions, legal and accounting fees, and other ancillary expenses.</p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">On <em style="font: inherit;"> February 2, 2021, </em>under the Shelf Registration Statement, the Company completed a bought deal offering of 10,000,000 shares of common stock at an offering price of $1.44 per share. As a result, the Company received aggregate net proceeds of approximately $13.1 million after underwriting discounts, commissions, legal and accounting fees, and other ancillary expenses.</p>
CY2021Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-374800000	USD
CY2021Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	26700000	USD
CY2020Q2	us-gaap	Product Warranty Accrual Warranties Issued ProductWarrantyAccrualWarrantiesIssued	50000	USD
	us-gaap	Product Warranty Accrual Warranties Issued ProductWarrantyAccrualWarrantiesIssued	41000	USD
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Use of Estimates</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts and disclosures reported in the financial statements. Management uses significant judgment when making estimates related to its stock-based compensation, accruals related to compensation, the valuation of the common stock warrants, provisions for doubtful accounts receivable and excess and obsolete inventories, clinical trial accruals, and its reserves for sales returns and warranty costs. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are <em style="font: inherit;">not</em> readily apparent from other sources. Although these estimates are based on the Company’s knowledge of current events and actions it <em style="font: inherit;"> may </em>undertake in the future, actual results <em style="font: inherit;"> may </em>ultimately materially differ from these estimates and assumptions.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p>
CY2021Q1	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	211000	USD
CY2020Q1	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	221000	USD
CY2020Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	193000	USD
CY2019Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	215000	USD
CY2021Q2	us-gaap	Product Warranty Accrual Warranties Issued ProductWarrantyAccrualWarrantiesIssued	21000	USD
CY2021Q2	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.065	pure
	us-gaap	Product Warranty Accrual Warranties Issued ProductWarrantyAccrualWarrantiesIssued	111000	USD
CY2021Q2	avgr	Product Warranty Accrual Payments And Release ProductWarrantyAccrualPaymentsAndRelease	1000	USD
CY2020Q2	avgr	Product Warranty Accrual Payments And Release ProductWarrantyAccrualPaymentsAndRelease	50000	USD
	avgr	Product Warranty Accrual Payments And Release ProductWarrantyAccrualPaymentsAndRelease	3000	USD
	avgr	Product Warranty Accrual Payments And Release ProductWarrantyAccrualPaymentsAndRelease	105000	USD
CY2021Q2	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	231000	USD
CY2020Q2	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	221000	USD
CY2021Q2	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	231000	USD
CY2020Q2	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	221000	USD
CY2021Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3496000	USD
CY2020Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4967000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-9592000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-11785000	USD
CY2021Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	95352000
CY2020Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	27310000
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	93404000
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	20963000
CY2021Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.04
CY2020Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.18
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.10
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.56
CY2021Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3235772
CY2020Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3649439
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3234868
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3666451
CY2021Q2	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1721000	USD
CY2020Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1792000	USD
CY2021Q2	us-gaap	Inventory Net InventoryNet	4118000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	3876000	USD
CY2021Q2	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	1974000	USD
CY2020Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	1904000	USD
CY2021Q2	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	423000	USD
CY2020Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	180000	USD
CY2019Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	5800000	USD
CY2021Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y4M24D
CY2021Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	52276
CY2018Q1	avgr	Proceeds From Issuance Or Sale Of Equity Net ProceedsFromIssuanceOrSaleOfEquityNet	15500000	USD
CY2021Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2021Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	95353002
CY2021Q2	avgr	Operating Lease Expense Excluding Maintenance Fee And Other Expense Monthly OperatingLeaseExpenseExcludingMaintenanceFeeAndOtherExpenseMonthly	105000	USD
CY2020Q2	us-gaap	Operating Lease Expense OperatingLeaseExpense	314000	USD
	us-gaap	Operating Lease Expense OperatingLeaseExpense	628000	USD
CY2021Q2	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	253000	USD
CY2020Q2	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	239000	USD
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	502000	USD
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	475000	USD
CY2021Q2	us-gaap	Prepaid Rent PrepaidRent	223000	USD
CY2021Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	563000	USD
CY2021Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1162000	USD
CY2021Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1203000	USD
CY2021Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1138000	USD
CY2021Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	4066000	USD
CY2021Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	436000	USD
CY2021Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	3630000	USD
CY2021Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2021Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	27539986
CY2021Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	2753999
CY2020Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	2753999
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6821000
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1241.59
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y9M21D
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	134000
CY2021Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	2546690
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6687000
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1215.43
CY2021Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y4M24D
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	6687000
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	1215.43
CY2021Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y4M24D
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	6687000
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	1215.43
CY2021Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P5Y4M24D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0
CY2021Q2	us-gaap	Share Price SharePrice	1.23
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	776000	USD
CY2021Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	303000	USD
CY2020Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	325000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	721000	USD

Files In Submission

Name	View Source	Status
0001437749-21-019333-index-headers.html	Edgar Link	pending
0001437749-21-019333-index.html	Edgar Link	pending
0001437749-21-019333.txt	Edgar Link	pending
0001437749-21-019333-xbrl.zip	Edgar Link	pending
avgr-20210630.xsd	Edgar Link	pending
avgr-20210630_cal.xml	Edgar Link	unprocessable
avgr-20210630_def.xml	Edgar Link	unprocessable
avgr-20210630_lab.xml	Edgar Link	unprocessable
avgr-20210630_pre.xml	Edgar Link	unprocessable
avgr20210630_10q.htm	Edgar Link	pending
avgr20210630_10q_htm.xml	Edgar Link	completed
ex_271046.htm	Edgar Link	pending
ex_271047.htm	Edgar Link	pending
ex_271048.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AVGR
Avinger Inc Stock $avgr

2021 Q3 Form 10-Q Financial Statement

#000143774921019333 Filed on August 10, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AVGR Avinger Inc Stock $avgr

2021 Q3 Form 10-Q Financial Statement

#000143774921019333 Filed on August 10, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AVGR
Avinger Inc Stock $avgr